# The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06117137` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06117137](<https://clinicaltrials.gov/study/NCT06117137>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06117137

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT06117137. Randomized; no masking; primary purpose treatment. Start 2023-11-15 (actual); primary completion 2025-01-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT06117137, source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)
- Started: 2023-11-15 (actual) (ClinicalTrials.gov record NCT06117137, source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)
- Primary completion: 2025-01-01 (actual) (ClinicalTrials.gov record NCT06117137, source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)
- Completion: 2026-04-03 (actual) (ClinicalTrials.gov record NCT06117137, source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06117137, source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06117137-2026-04-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
- Condition: Fatty Liver, Nonalcoholic
- Intervention (Drug): SGLT2 inhibitor
- Lead sponsor: Sohag University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Sohag University (`cardio:org-sohag-university`)

## Provenance

Content hash: b9a11351545785c1442731f7be7978cb3b9f0ad62b9a4fc76e721cf4a1fb5361
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
